Products
Platform
Research
Market
Learn
Compare DSP Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.93 | 1.88 |
NAV | ₹39.07 | ₹39.66 |
Fund Started | 12 Nov 2018 | 25 Jun 2018 |
Fund Size | ₹3190.15 Cr | ₹6103.96 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.93
1.88
NAV
₹39.07
₹39.66
Fund Started
12 Nov 2018
25 Jun 2018
Fund Size
₹3190.15 Cr
₹6103.96 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 0.05% | 3.69% |
3 Year | 24.67% | 28.18% |
5 Year | 18.26% | 21.45% |
1 Year
0.05%
3.69%
3 Year
24.67%
28.18%
5 Year
18.26%
21.45%
Holding Analysis
Equity | 97.58% | 95.89% |
Cash | 2.42% | 4.11% |
Equity
97.58%
95.89%
Cash
2.42%
4.11%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Cipla Ltd. | 8.73% |
Sun Pharmaceutical Industries Ltd. | 8.22% |
Ipca Laboratories Ltd. | 7.84% |
Cohance Lifesciences Ltd. | 7.79% |
Laurus Labs Ltd. | 6.08% |
Gland Pharma Ltd. | 5.96% |
Apollo Hospitals Enterprise Ltd. | 4.58% |
Illumina Inc. (USA) | 4.52% |
Alembic Pharmaceuticals Ltd. | 4.38% |
Sai Life Sciences Ltd. | 4.32% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.69% |
Dr. Reddy's Laboratories Ltd. | 8.85% |
Divi's Laboratories Ltd. | 8.13% |
Cipla Ltd. | 7.54% |
Aurobindo Pharma Ltd. | 5.71% |
Lupin Ltd. | 5.11% |
Mankind Pharma Ltd. | 3.88% |
Alkem Laboratories Ltd. | 3.83% |
Biocon Ltd. | 3.64% |
Gland Pharma Ltd. | 3.20% |
Fund Manager
Name | Jay Kothari | Dharmesh Kakkad |
Start Date | 16 Mar 2018 | 23 Feb 2021 |
Name
Jay Kothari
Dharmesh Kakkad
Start Date
16 Mar 2018
23 Feb 2021
About Fund
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 12 Nov 2018 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
12 Nov 2018
25 Jun 2018
